
NAMS Stock Forecast & Price Target
NAMS Analyst Ratings
Bulls say
NewAmsterdam Pharma Co is supported by a lead asset, obicetrapib, that has repeatedly shown meaningful LDL-C reductions, a clean safety profile, and practical oral once-daily dosing, all of which address clear gaps left by statins and injectable PCSK9 inhibitors. The bull case is further strengthened by a large unmet need in cardiovascular disease, with up to 50% of U.S. patients not reaching cholesterol goals and 9–15% unable to tolerate statins, while management believes a 40% LDL lowering can translate into a 20% lower MACE risk and support a >90% powered outcomes trial. In addition, the company’s cash balance of about $643MM and expected support through PREVAIL results and initial U.S. launch reduce financing pressure, while ex-U.S. milestones of up to €817MM and double-digit royalties add meaningful long-term optionality.
Bears say
NewAmsterdam Pharma Co is viewed negatively because its value hinges on a binary PREVAIL interim analysis in 4Q26, where the weaker MACE-3 endpoint appears to be the real hurdle and the modeled probability of success is only about 25% to 40%, versus a more optimistic 50% earlier estimate. Even if obicetrapib succeeds, the company still faces substantial clinical, regulatory, reimbursement, and commercialization risks, while competing against statins, PCSK9s, and other large-pharma therapies in a crowded market. With no current products on market, escalating R&D and launch costs, and a composition-of-matter patent expiring in 2027, it may need additional capital and still struggle to prove durable, profitable demand.
This aggregate rating is based on analysts' research of Newamsterdam Pharma Co NV and is not a guaranteed prediction by Public.com or investment advice.
NAMS Analyst Forecast & Price Prediction
Start investing in NAMS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Newamsterdam Pharma Co NV (NAMS) Forecast
NAMS Analyst Forecast & Price Prediction
Start investing in NAMS
Order type
Buy in
Order amount
Est. shares
0 shares